



Q1 2026 RESULTS

Strong execution across key focus areas.
Updated full year 2026 guidance.
Progress across a growing pipeline.

Q1 FINANCIALS

Q1 Revenue

\$1.5B

+ 35% from prior-year period

Net Income

\$227M

GAAP diluted earnings per ADS of \$1.96

Gross Margin

89%

from ~85% prior year period

COMMERCIAL HIGHLIGHTS



+38%

Sustained global, foundational BTKi leadership



+20%

Continued China leadership

Sonrotoclax*

Launched in China in R/R CLL and R/R MCL; U.S. PDUFA for R/R MCL in Q2

PIPELINE HIGHLIGHTS

- ✦ >60 acceptances at ASCO and EHA
- ✦ Multiple milestones expected Q2 from foundational hematology franchise
- ✦ CDK4i 1L Ph3 FSE in Q2
- ✦ GPC3 X 4-1BB pivotal trial initiated

**CANCER
HAS NO BORDERS
NEITHER
DO WE**

*Brand names vary by country.